Skip to main content
. Author manuscript; available in PMC: 2010 Mar 4.
Published in final edited form as: Vaccine. 2009 Jan 23;27(10):1549–1556. doi: 10.1016/j.vaccine.2009.01.010

Figure 2.

Figure 2

Anti-VV NAb and cellular immune responses elicited by rVV, rMVA, and rFPV vaccine vectors. Plasma and PBMC samples were obtained from vaccinated monkeys 4 weeks following boost immunizations with either plasmid DNA, rFPV, rMVA or rVV. (A) Serial dilutions of plasma samples were tested for NAb activity against VV:Luc. Data are presented as the mean ID50 neutralization titer from seven monkeys per group +/- SEM. The dashed line represents the assay limit of detection (ID50 titer >20). PBMC were assessed for IFN-γ ELISPOT responses against VV:WR (B) or the vaccine insert, HIV-1 Gag (C). Data are presented as the mean number of antigen-specific SFC per 106 PBMC +/- SEM from seven monkeys per group.